Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Tempus said the FDA cleared its ECG-MR AI product, which analyzes 12-lead ECGs to detect signs associated with undiagnosed moderate or severe mitral regurgitation. The company said ECG-MR is its fourth FDA-cleared ECG-AI product.
TEM Tempus received FDA clearance for its AI product intended to detect signs of pulmonary hypertension from standard ecgs.
TEM Tempus says it receives FDA clearance for its AI product intended to detect signs of pulmonary hypertension from standard ECGs.